Understanding how certain cells contribute to aggressive breast cancer
Delineating developmental programs driving tumorigenesis in triple-negative breast cancer
This study is looking at how certain immature cancer cells in triple-negative breast cancer might make the disease tougher to treat, and it aims to find new ways to target these cells to help improve treatment for over 800 patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11036265 on NIH RePORTER |
What this research studies
This research investigates the role of immature cancer cells in triple-negative breast cancer (TNBC), a particularly aggressive form of breast cancer. By analyzing single-cell RNA sequencing data, the study aims to identify specific cellular characteristics that contribute to tumor growth and drug resistance. The researchers will focus on over 800 TNBC patients to explore how these immature cells can be targeted for new treatment strategies. The goal is to improve patient outcomes by developing more effective therapies based on the unique biology of these cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer.
Not a fit: Patients with non-triple-negative breast cancer subtypes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that specifically target the aggressive cells in TNBC, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in targeting specific cancer cell populations, suggesting that this approach could yield significant advancements in treatment.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Newman, Aaron M — Stanford University
- Study coordinator: Newman, Aaron M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.